Therapeutic use of avidin is not hampered by antiavidin antibodies in humans

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 5, 2010, Pages 563-570

  Petronzelli, Fiorella ^a   Pelliccia, Angela ^a   Anastasi, Anna Maria ^a   Lindstedt, Ragnar ^a   Manganello, Stefania ^a   Ferrari, Liliana Elisa ^a   Albertoni, Claudio ^a   Leoni, Barbara ^a   Rosi, Antonio ^a   D'Alessio, Valeria ^a   Deiana, Katia ^a   Paganelli, Giovanni ^b   De Santis, Rita ^a  

^a Sigma Tau SpA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

antibody; avidin; HAVA; immunogenicity; radioimmunotherapy; targeted therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AVIDIN; BIOTIN; HUMAN AVIDIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SERUM;

ANIMALS; ANTIBODIES; AVIDIN; BIOTIN; HUMANS; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; NEOPLASMS; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION;

EID: 77958155248     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0797     Document Type: Article

References (37)

1. Melamed MD, Green NM. Avidin. Purification and composition. Biochem J 1963;89:591.
2. Green NM. Avidin. The nature of the biotin-binding site. Biochem J 1963;89:599.
3. Paganelli G, Grana C, Chinol M, et al. Antibody-guided three step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999;26:348.
4. Cremonesi M, Ferrari M, Chinol M, et al. Three-step radioimmunotherapy with yttrium-90 biotin: Dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med 1999;26:110.
5. Grana C, Chinol M, Robertson C, et al. Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study. Br J Cancer 2002;86:207.
6. Grana C, Bartolomei M, Handkiewicz D, et al. Radioimmunotherapy in advanced ovarian cancer: Is there a role for pre-targeting with 90Y-biotin? Gynecol Oncol 2004;93:691.
7. Palumbo G, Grana CM, Cocca F, et al. Pretargeted antibodyguided radioimmunotherapy in a child affected by resistant anaplastic large cell lymphoma. Eur J Haematol 2007;79:258.
8. Yao Z. Zhang M, Sakahara H, et al. Avidin targeting of intraperitoneal tumor xenografts. J Natl Cancer Inst 1998;90:25.
9. Yao, Z., Zhang M, Sakahara H, et al. The relationship of glycosylation and isoelectric point with tumor accumulation of avidin. J Nucl Med 1999;40:479.
10. Chinol M, De Cobelli O, Trifiro G, et al. Localization of avidin in superficial bladder cancer: A potentially new approach for radionuclide therapy. Eur Urol 2003;44:556.
11. ®: Intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation. Breast 2007;16:17.
12. Paganelli G, Ferrari M, Ravasi L, et al. Intraoperative avidination for radionuclide therapy: A prospective new development to accelerate radiotherapy in breast cancer. Clin Cancer Res 2007;13(18 Suppl): 5646.
13. Paganelli G, De Cicco C, Ferrari ME, et al. Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: Results of a phase II study with (90) Y-labeled biotin. Eur J Nucl Med Mol Imaging 2010;37:203.
14. Rosebrough SF. Pharmacokinetics and biodistribution of radiolabeled avidin, streptavidin and biotin. Nucl Med Biol 1993;20:663.
15. Veyrat-Follet C, Vivier N, Trellu M, et al. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: Population pharmacokinetic analysis from phase III clinical trials. J Thromb Haemost 2009;7:559.
16. Bubb MO, Green F, Conradie JD, et al. Natural antibodies to avidin in human serum. Immunol Lett 1993;35:277.
17. Dale GL, Gaddy P, Pikul FJ. Antibodies against biotinylated proteins are present in normal human serum. J Lab Clin Med 1994;123:365.
18. Cox JE, Cheng TL. Egg-based vaccines. Pediatr Rev 2006;27:118.
19. ®). Eur J Nucl Med Mol Imaging 2007;34:68.
20. ®). Br J Cancer 2003;88:996.
21. Paganelli G, Chinol M, Stoldt SH, et al. Radioimmunotherapy using the avidin-biotin pretargeting approach. In: Riva P, ed., Cancer Radioimmunotherapy: Present and Future. Amsterdam, The Netherlands: Harwood Academic Publisher, 1998:123.
22. Li GP, Zhang H, Zhu CM, et al. Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma. World J Gastroenterol 2005;11:6288.
23. Salmaso S, Bersani S, Pennadam SS, et al. Avidin bioconjugate with a thermoresponsive polymer for biological and pharmaceutical applications. Int J Pharmaceutics 2007;340:20.
24. Subramanian N, Adiga PR. Mapping the common antigenic determinants in avidin and streptavidin. Biochem Mol Biol Int 1997;43:375.
25. Chinol M, Casalini P, Maggiolo M, et al. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer 1998;78:189.
26. Meyer DL, Schultz J, Lin Y, et al. Reduced antibody response to streptavidin through site-directed mutagenesis. Protein Sci 2001;10:491.
27. Samuel A, Paganelli G, Chiesa R, et al. Detection of prosthetic vascular graft infection using avidin/Indium-111-biotin scintigraphy. J Nucl Med 1996;37:55.
28. Paganelli G, Chinol M, Maggiolo M. The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. Eur J Nucl Med 1997;24:350.
29. Grana C, Chinol M, Robertson C, et al. Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study. Br J Cancer 2002;86:207.
30. Lehtolainen P, Taskinen A, Laukkanen J, et al. Cloning and characterization of Scavidin, a fusion protein for the targeted delivery of biotinylated molecules. J Biol Chem 2002;277:8545.
31. Bickel U, Yoshikawa T, Landaw EM, et al. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc Natl Acad Sci USA 1993;90:2618.
32. Ponnazhagan S, Mahendra G, Kumar S, et al. Conjugatebased targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J Virol 2002;76:12900.
33. Emile Gras JC, Verkuijlen P, Frants RR, et al. Specific and efficient targeting of adenovirus vectors to macrophages: Application of a fusion protein between an adenovirusbinding fragment and avidin, linked to a biotinylated oligonucleotide. J Gene Med 2006;8:668.
34. Zavaleta A, Phillips WT, Soundararajan A, et al. Use of avidin/biotin-liposome system for enhanced peritoneal drug delivery in an ovarian cancer model. Int J Pharm 2007;337:316.
35. De Santis R, Albertoni C, Rosi A, et al. OXavidin for tissue targeting biotinylated therapeutics. J Biomed Biotechnol 2009; published online January 10, 2010, doi: 10.1155/2009/921434.
36. Verdoliva A, Bellofiore P, Rivieccio V, et al. Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties. J Biol Chem 2010;285:9090.
37. ™ for highly efficient tissue-pretargeted radionuclide therapy. Cancer Biother Radiopharm 2010;25:143.